Engineered Extracellular Vesicles with SHP2 High Expression Promote Mitophagy for Alzheimer's Disease Treatment
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Mitochondrial dysfunction is a fundamental pathological feature of Alzheimer's disease (AD). However, toxicity and poor brain enrichment of existing mitophagy inducers limit their further applications. In this study, a platform for AD therapy is developed using nanosized mesenchymal‐stem‐cells‐derived extracellular vesicles with tyrosine phosphatase‐2 (SHP2) high‐expression (MSC‐EVs‐SHP2). The high blood–brain barrier penetration ability of MSC‐EVs‐SHP2 is demonstrated in AD‐mice, facilitating SHP2 delivery to the brain. In addition, MSC‐EVs‐SHP2 significantly induces mitophagy of neuronal cells, which alleviates mitochondrial damage‐mediated apoptosis and NLRP3 inflammasome activation. Mitophagy further diminishes neuronal cells apoptosis and neuroinflammation, culminating with rescued synaptic loss and cognitive decline in an AD mouse model. The EV‐engineering technology provides a potential platform for effective AD therapy by inducing mitophagy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
RNA delivery by extracellular vesicles in mammalian cells and its applications
O’Brien, K., Breyne, K., Ughetto, S., Laurent, L. C., & Breakefield, X. O. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0251-y · Cited by 1,811
Fang, E. F., Hou, Y., Palikaras, K., Adriaanse, B. A., Kerr, J. S., Yang, B., Lautrup, S., Hasan-Olive, M. M., Caponio, D., Dan, X., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0332-9 · Cited by 1,740
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Self-citationLee, J.-H., Yang, D.-S., Goulbourne, C. N., Im, E., Stavrides, P., Pensalfini, A., Chan, H., Bouchet-Marquis, C., Bleiwas, C., Berg, M. J., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01084-8 · Cited by 638
Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity
Sorrentino, V., Romani, M., Mouchiroud, L., Beck, J. S., Zhang, H., D’Amico, D., Moullan, N., Potenza, F., Schmid, A. W., Rietsch, S., et al. (2017) · Nature · doi:10.1038/nature25143 · Cited by 630
Kent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02196-w · Cited by 446
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
Palanisamy, C. P., Pei, J., Alugoju, P., Anthikapalli, N. V. A., Jayaraman, S., Veeraraghavan, V. P., Gopathy, S., Roy, J. R., Janaki, C. S., Thalamati, D., et al. (2023) · Theranostics · doi:10.7150/thno.83066 · Cited by 165
“EV-engineering can be used to induce mitophagy in AD patients, providing an effective treatment option [186].”
BackgroundAmyloid Precursor Protein and Alzheimer’s Disease
Orobets, K. S., & Karamyshev, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914794 · Cited by 141
“…SHP2 to the brain, where it induces mitophagy and helps with the clearance of aberrant proteins [123,124]. derived extracellular vesicles (EVs) with tyrosine phosphatase ‐ 2 (SHP2) deliver SHP2 to the brain, where it induces mi ‐ tophagy and helps with the clearance of aberrant proteins [123,124].”
BackgroundExtracellular vesicles: New horizons in neurodegeneration
Chen, J., Tian, C., Xiong, X., Yang, Y., & Zhang, J. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105605 · Cited by 53
Liu, X., Shen, L., Wan, M., Xie, H., & Wang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02428-1 · Cited by 33
“Similarly, bioactive compounds such as quercetin and curcumin, as well as protein modulators like tyrosine phosphatase-2 (SHP2), have been efficiently packaged within EVs, providing a therapeutic thrust against hyperphosphorylated tau and mitochondrial dysfunction associated with AD [151–153].”
Background
Metadata
- Authors
- Xu, F., Wu, Y., Yang, Q., Cheng, Y., Xu, J., Zhang, Y., Dai, H., Wang, B., Ma, Q., Chen, Y., Lin, F., & Wang, C.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2022-11
- Volume
- 34
- Issue
- 49
- Pages
- e2207107-e2207107
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W4301391517
- Cited by
- 147
- References
- 15
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered Extracellular Vesicles with SHP2 High Expression Promote Mitophagy for Alzheimer's Disease Treatment. https://app.cochat.ai/papers/10.1002/adma.202207107
- The paper
- Xu, F., Wu, Y., Yang, Q., Cheng, Y., Xu, J., Zhang, Y., Dai, H., Wang, B., Ma, Q., Chen, Y., Lin, F., & Wang, C. (2022). Engineered Extracellular Vesicles with SHP2 High Expression Promote Mitophagy for Alzheimer's Disease Treatment. Advanced Materials. https://doi.org/10.1002/adma.202207107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.